CYRX

CryoPort, Inc. (CYRX) - 10-K Summary for Fiscal Year Ended March 31, 2010

Business Context and Reporting Period

CryoPort, Inc. is a provider of cryogenic shipping solutions, specifically the CryoPort Express® System, which includes dry vapor shippers, a web portal, and data loggers for transporting temperature-sensitive biological and pharmaceutical materials. The company shifted its business model from selling reusable shippers to a per-use leasing model with value-added services. This report covers the fiscal year ended March 31, 2010. On February 5, 2010, the company effected a 10-for-1 reverse stock split.

Key Financial Metrics

Note: The Net Loss for 2010 includes a non-cash gain of $5,576,979 related to the change in fair value of derivative liabilities.

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 236% to $118,000, driven by the shift to per-use leasing of shipping containers, though costs of revenues also increased significantly due to fixed manufacturing costs and plant underutilization.
• Net Loss Reduction: Net loss decreased significantly from $16.7 million to $5.7 million. This improvement was largely due to a $5.6 million non-cash gain from the revaluation of derivative liabilities and the absence of the $10.8 million loss on extinguishment of debt recorded in 2009.
• Liquidity Improvement: Cash balances surged from $250,000 to $3.6 million, primarily due to a public offering of units in February 2010 (net proceeds ~$3.7 million) and proceeds from private placement debentures.
• Debt Restructuring: The company amended its convertible debentures in 2010, converting a portion of principal to equity and resetting conversion prices, which eliminated certain derivative liabilities and anti-dilution provisions.

Guidance, Outlook, and Risks

• Going Concern: Auditors have expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows. Management estimates cash on hand will sustain operations only into the second quarter of fiscal 2011 (ending September 2010).
• Strategic Partnership: In January 2010, CryoPort signed an agreement with FedEx to lease shippers and promote CryoPort services. However, the agreement contains no minimum purchase requirements, and revenue impact remains uncertain.
• Capital Needs: The company must raise additional capital to fund operations beyond mid-2011 and to commercialize the CryoPort Express® System. No current arrangements for additional financing exist.
• Debt Covenants: Outstanding convertible debentures impose restrictive covenants, including limits on additional indebtedness, dividends, and stock splits. All assets, including intellectual property, are pledged as collateral.
• Market Risks: The company faces risks related to the acceptance of its new business model, competition from dry ice and other cryogenic shippers, and the volatility of its stock price (traded on OTC Bulletin Board).

Investor Verification Checklist

• Cash Runway: Verify the company's ability to raise capital before the projected cash exhaustion in Q2 Fiscal 2011.
• FedEx Agreement Execution: Monitor whether the FedEx partnership generates material revenue, given the lack of minimum order commitments.
• Debt Maturity: Review the repayment schedule for convertible debentures, which require monthly principal payments of $200,000 commencing March 1, 2011.
• Derivative Accounting: Understand the impact of derivative liability revaluations on reported net income, as these are non-cash items that significantly distort operating performance.
• Customer Concentration: Note that two customers (BD Biosciences and CDx Holdings) accounted for over 50% of revenues in 2010.